Classen Immunotherapies, Inc. v. King Pharmaceuticals, Inc.
981 F. Supp. 2d 415
D. Maryland2013Background
- Classen sues Elan for infringement of the 472 and 674 patents; 674 later deemed invalid following PTO reexamination.
- Case stayed pending PTO reexamination; the stay has since completed and the Court vacates the prior summary judgment in part.
- Court previously granted Elan summary judgment on infringement under 35 U.S.C. § 271(e)(1) safe harbor for FDA-related activity.
- Classen moved in 2012 to lift the stay, reopen the case, and dismiss claims based on the invalid 674 patent; Elan opposed.
- Court retains jurisdiction over the unenforceability counterclaim related to the 674 patent despite its invalidity; Court denies most reconsideration arguments and lifts the stay.
- Decision: grant in part and deny in part the motion to lift the stay; dismiss defenses/counterclaims related to the 674 patent except unenforceability; denial of reconsideration of the summary judgment order.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether to dismiss claims based on the invalid 674 patent. | Classen seeks dismissal of 674-based claims. | Elan agrees dismissal of 674-based claims except unenforceability. | Partial dismissal granted; 674-related defenses/counterclaims dismissed except unenforceability. |
| Whether to retain jurisdiction over the unenforceability counterclaim. | (not separately stated) | Retain jurisdiction per Monsanto for inequitable conduct inquiry. | Court retains jurisdiction over unenforceability counterclaim. |
| Whether to reconsider/alter the summary judgment under Rule 60(b) based on Classen/Biogen and Momenta. | Arguments warrant reconsideration in light of Biogen decision. | Safe harbor analysis remains valid per Momenta and Classen. | Motion to reconsider denied; safe harbor remains valid. |
| Whether Elan’s activities fall within § 271(e)(1) safe harbor after Momenta/Classen. | Safe harbor did not cover this activity. | Activities were reasonably related to FDA information submission. | Safe harbor applied; Elan’s activities are protected. |
| Whether the stay should be lifted and the case reopened. | Stay lifted; case reopened to proceed with remaining claims. |
Key Cases Cited
- Monsanto Co. v. Bayer Bioscience N.V., 514 F.3d 1229 (Fed.Cir.2008) (retains jurisdiction over unenforceability claims after patent withdrawal for fees)
- Fort James Corp. v. Solo Cup Co., 412 F.3d 1340 (Fed.Cir.2005) (unenforceability raises issues beyond non-infringement)
- Nilssen v. Osram Sylvania, Inc., 504 F.3d 1223 (Fed.Cir.2007) (infectious unenforceability taught; related applications not disposed by non-infringement)
- Fox Indus., Inc. v. Structural Pres. Sys., Inc., 922 F.2d 801 (Fed.Cir.1990) (breach of duty of candor may render related claims unenforceable)
- Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (Supreme Court 2005) (broad view of safe harbor scope under FDA regulatory information)
- Momenta Pharmaceuticals, Inc. v. Amphastar Pharm., Inc., 686 F.3d 1348 (Fed.Cir.2012) (safe harbor expansive; post-approval studies may be covered if related to regulatory information)
- Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057 (Fed.Cir.2011) (scope of § 271(e)(1) post-Momenta; routine reporting versus information-expediting)
- Classen Immunotherapies, Inc. v. Biogen IDEC (Md. 2005), 381 F. Supp. 2d 452 (D. Md. 2005) (district court analysis on safe harbor applicability)
- Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S, 132 S. Ct. 1670 (Supreme Court 2012) (extensive interpretation of information submitted under federal law)